| Monoclonal antibody | |
|---|---|
| Type | Single-chain variable fragment |
| Source | Humanized |
| Target | EpCAM |
| Clinical data | |
| Other names | oportuzumab monatox-qqrs |
| ATC code | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C3072H4723N877O952S12 |
| Molar mass | 69558.48 g·mol−1 |
  (what is this?) (verify) | |
Oportuzumab monatox is an experimental anti-cancer medication. Chemically, oportuzumab is a single chain variable fragment of a monoclonal antibody which binds to epithelial cell adhesion molecule (EpCAM, the tumor-associated calcium signal transducer 1). Oportuzumab is fused with Pseudomonas aeruginosa exotoxin A (which is reflected by the monatox in the medication's name).[1]
The drug was developed by Canadian-based Viventia Bio Inc. The company was acquired by Cambridge(MA)-based Eleven Biotherapeutics in 2016, which then changed its name to Sesen Bio.[2] In 2019 Sesen Bio reported updated, preliminary primary and secondary endpoint data from the company's Phase 3 VISTA trial further supporting the strong benefit-risk profile of Vicineum for the potential treatment of patients with high-risk, bacillus Calmette-Guérin(BCG) unresponsive, non-muscle invasive bladder cancer (NMIBC).[3] The Company applied for approval of Vicineum by the United States Food and Drug Administration and the European Medicines Agency.
- ^ International Nonproprietary Names for Pharmaceutical Substances (INN, prepublication copy), World Health Organization.
- ^ Alex Keown: Eleven Biotherapeutics Changes Name to Sesen Bio to Reflect Commitment to Oncology Therapies. Biospace.com, May 16, 2018.
- ^ Sesen Bio Reports Positive, Preliminary Data Update from Phase 3 VISTA Trial for High-Risk Non-Muscle Invasive Bladder Cancer. Businesswire.com, August 8, 2019